These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 25619125)

  • 41. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
    Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
    J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Bates SM; Greer IA; Hirsh J; Ginsberg JS
    Chest; 2004 Sep; 126(3 Suppl):627S-644S. PubMed ID: 15383488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Büller HR; Agnelli G; Hull RD; Hyers TM; Prins MH; Raskob GE
    Chest; 2004 Sep; 126(3 Suppl):401S-428S. PubMed ID: 15383479
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
    De A; Roy P; Garg VK; Pandey NK
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):57-61. PubMed ID: 19844176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial.
    Daskalopoulos ME; Daskalopoulou SS; Tzortzis E; Sfiridis P; Nikolaou A; Dimitroulis D; Kakissis I; Liapis CD
    Eur J Vasc Endovasc Surg; 2005 Jun; 29(6):638-50. PubMed ID: 15878544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
    van Rein N; Biedermann JS; van der Meer FJM; Cannegieter SC; Wiersma N; Vermaas HW; Reitsma PH; Kruip MJHA; Lijfering WM
    J Thromb Haemost; 2017 Jul; 15(7):1386-1391. PubMed ID: 28440008
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
    Borentain M; Montalescot G; Bouzamondo A; Choussat R; Hulot JS; Lechat P
    Catheter Cardiovasc Interv; 2005 Jun; 65(2):212-21. PubMed ID: 15900551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients.
    Davidson BL
    Haemostasis; 2000; 30 Suppl 2():77-81; discussion 63. PubMed ID: 11251346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute pulmonary embolism in cancer patients admitted to intensive care unit: Impact of anticoagulant treatment on 90-day mortality and risk factors, results of a multicentre retrospective study.
    Mokart D; Serre E; Bruneel F; Kouatchet A; Lemiale V; Chow-Chine L; Faucher M; Sannini A; Valade S; Bisbal M; Gonzalez F; Servan L; Darmon M; Azoulay E
    Thromb Res; 2024 May; 237():129-137. PubMed ID: 38583310
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of LMWH versus UFH for hemorrhage and hospital mortality in the treatment of acute massive pulmonary thromboembolism after thrombolytic treatment : randomized controlled parallel group study.
    Ucar EY; Akgun M; Araz O; Tas H; Kerget B; Meral M; Kaynar H; Saglam L
    Lung; 2015 Feb; 193(1):121-7. PubMed ID: 25351610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term treatment of venous thromboembolism with low-molecular-weight heparin.
    Monreal M
    Curr Opin Pulm Med; 2000 Jul; 6(4):326-9. PubMed ID: 10912641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Elliott G; Stein PD; Gottschalk A; Valentine KA; Mah AF
    Arch Intern Med; 2000 Jan; 160(2):229-36. PubMed ID: 10647762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Vardi M; Zittan E; Bitterman H
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006771. PubMed ID: 19821386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.
    Schutgens RE; Esseboom EU; Snijder RJ; Haas FJ; Verzijlbergen F; Nieuwenhuis HK; Lisman T; Biesma DH
    J Lab Clin Med; 2004 Aug; 144(2):100-7. PubMed ID: 15322504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
    Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
    Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis.
    Beitland S; Sandven I; Kjærvik LK; Sandset PM; Sunde K; Eken T
    Intensive Care Med; 2015 Jul; 41(7):1209-19. PubMed ID: 25971389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-molecular weight heparins in venous and arterial thrombotic disease.
    Bijsterveld NR; Hettiarachchi R; Peters R; Prins MH; Levi M; Büller HR
    Thromb Haemost; 1999 Sep; 82 Suppl 1():139-47. PubMed ID: 10695506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.
    Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC;
    J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.